Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

• Main Authors: Antonio Costanzo (Author), Filomena Russo (Author), Marco Galluzzo (Author), Luca Stingeni (Author), Roberta Scuderi (Author), Leonardo Zichichi (Author), Manuela Papini (Author), Luisa Di Costanzo (Author), Andrea Conti (Author), Martina Burlando (Author), Andrea Chiricozzi (Author), Francesca Maria Gaiani (Author), Cristina Mugheddu (Author), Maria Letizia Musumeci (Author), Paolo Gisondi (Author), Stefano Piaserico (Author), Paolo Dapavo (Author), Marina Venturini (Author), Gianluca Pagnanelli (Author), Paolo Amerio (Author), Concetta Potenza (Author), Ketty Peris (Author), Franca Cantoresi (Author), Sara Trevisini (Author), Francesco Loconsole (Author), Annamaria Offidani (Author), Santo Raffaele Mercuri (Author), Viviana Lora (Author), Francesca Prignano (Author), Marta Bartezaghi (Author), Giovanni Oliva (Author), Elisabetta Aloisi (Author), Roberto Orsenigo (Author)
• Format: Book
• Published: Medical Journals Sweden, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Se...